-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, domestic and foreign pharmaceutical companies have intensively disclosed their 2022 semi-annual financial reports and performance forecast peri.
Up to now, the results of local pharmaceutical companies have been released one after another, and most multinational pharmaceutical companies have also announced the financial report data for the first half of the ye.
Overall, it's a mixed blessi.
Judging from the published data, in the first half of this year, there are not many multinational pharmaceutical companies whose performance has maintained growth, including Pfizer, Merck, BMS, Sanofi, Roche,e.
According to Pfizer’s performance report for the first half of 2022, the company achieved total revenue of US$54 billion, a year-on-year increase of 60%; net profit was US$1769 billion, a year-on-year increase of 7
From the perspective of performance contribution, the mRNA vaccine Comirnaty developed by the company and BioNTech has brought sales revenue of up to 2075 billion US dolla.
Merck's 2022 first half financial report shows that the company achieved a total revenue of US$3494 billion, a year-on-year increase of 41% after deducting exchange rate effec.
Among them, Molnupiravir (Monupiravir) achieved sales of 4 billion US dollars in the first half of the ye.
According to the company's previous forecast, the sales of molnupiravir will reach 5 billion to 6 billion US dollars in 2022, and the global sales in 2022 will be between 51 billion and 56 billion US dolla.
According to the BMS performance report for the first half of the year, the company achieved a total revenue of US$2535 billi.
Among them, the second quarter revenue was 19 billion US dollars, an increase of 2% year-on-ye.
Adjusted for foreign exchange effects, revenue increased 5% in the second quart.
During the reporting period, the company's mature products, including Eliquis (apixaban), Opdivo (nivolumab), and Yervoy (ipilimumab), all maintained high single-digit and double-digit growth, and total H1 revenue reached $195 billi.
In addition, newly launched innovative products are also seizing the market, including Abecma, Reblozyl, e.
, which have brought good performan.
According to Sanofi's financial report for the first half of 2022, the company achieved a total revenue of 179 billion euros, a year-on-year increase of 1
Among them, the blockbuster product Dupixent will still achieve rapid growth in the first half of 2022, with an operating income of 577 billion euros, a year-on-year increase of 4
It is worth mentioning that in the first half of the year, the growth rate of Sanofi China in China has reached 13%, which is almost the same as the growth rate of 14% in the United Stat.
The cumulative revenue contributed by China is 699 billion yuan, and that in the United States is 562 billion yu.
In the first half of 2022, Roche achieved revenue of CHF 3295 billion, a year-on-year increase of 5%, of which the revenue of the pharmaceutical sector was CHF 2347 billion, a year-on-year increase of 3%, and the revenue of the diagnostic business was CHF 948 billion, a year-on-year increase of 1
However, in the Chinese market, Roche's performance was not so brig.
The company said that due to the impact of biosimilars and the prevention and control of the new crown, the group's sales in China fell by
However, there are also some multinational pharmaceutical companies who are "worried" about their performance, such as Novartis and Johnson & Johns.
Novartis' first-half 2022 performance report shows that the company's net sales revenue in the first half of the year reached US$2312 billion, basically the same as the previous year; net profit was US$916 billion, down 297% year-on-year; operating income was US$2899 billion, down 34% year-on-ye.
According to Johnson & Johnson's financial report data for the first half of 2022, the company's total global revenue was US$4446 billion, a year-on-year increase of 4%, and its net profit was US$963 billion, a year-on-year decrease of 2
It is understood that due to the continuous decline of the global market due to the impact of biosimilar drugs, many of Johnson & Johnson's sales, including Remicade (infliximab) and Imbruvica (ibrutinib), have declined, of which Remicade even fell in the first half of the ye.
2
In summary, in the first half of this year, most multinational pharmaceutical companies that maintained rapid growth in performance were driven by vaccines and products, while those whose performance declined were mostly affected by biosimila.
Performance is still declini.
It is worth waiting to see how multinational pharmaceutical companies will respond to the challenges of biosimilars and product competition in the futu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Up to now, the results of local pharmaceutical companies have been released one after another, and most multinational pharmaceutical companies have also announced the financial report data for the first half of the ye.
Overall, it's a mixed blessi.
Judging from the published data, in the first half of this year, there are not many multinational pharmaceutical companies whose performance has maintained growth, including Pfizer, Merck, BMS, Sanofi, Roche,e.
According to Pfizer’s performance report for the first half of 2022, the company achieved total revenue of US$54 billion, a year-on-year increase of 60%; net profit was US$1769 billion, a year-on-year increase of 7
From the perspective of performance contribution, the mRNA vaccine Comirnaty developed by the company and BioNTech has brought sales revenue of up to 2075 billion US dolla.
Merck's 2022 first half financial report shows that the company achieved a total revenue of US$3494 billion, a year-on-year increase of 41% after deducting exchange rate effec.
Among them, Molnupiravir (Monupiravir) achieved sales of 4 billion US dollars in the first half of the ye.
According to the company's previous forecast, the sales of molnupiravir will reach 5 billion to 6 billion US dollars in 2022, and the global sales in 2022 will be between 51 billion and 56 billion US dolla.
According to the BMS performance report for the first half of the year, the company achieved a total revenue of US$2535 billi.
Among them, the second quarter revenue was 19 billion US dollars, an increase of 2% year-on-ye.
Adjusted for foreign exchange effects, revenue increased 5% in the second quart.
During the reporting period, the company's mature products, including Eliquis (apixaban), Opdivo (nivolumab), and Yervoy (ipilimumab), all maintained high single-digit and double-digit growth, and total H1 revenue reached $195 billi.
In addition, newly launched innovative products are also seizing the market, including Abecma, Reblozyl, e.
, which have brought good performan.
According to Sanofi's financial report for the first half of 2022, the company achieved a total revenue of 179 billion euros, a year-on-year increase of 1
Among them, the blockbuster product Dupixent will still achieve rapid growth in the first half of 2022, with an operating income of 577 billion euros, a year-on-year increase of 4
It is worth mentioning that in the first half of the year, the growth rate of Sanofi China in China has reached 13%, which is almost the same as the growth rate of 14% in the United Stat.
The cumulative revenue contributed by China is 699 billion yuan, and that in the United States is 562 billion yu.
In the first half of 2022, Roche achieved revenue of CHF 3295 billion, a year-on-year increase of 5%, of which the revenue of the pharmaceutical sector was CHF 2347 billion, a year-on-year increase of 3%, and the revenue of the diagnostic business was CHF 948 billion, a year-on-year increase of 1
However, in the Chinese market, Roche's performance was not so brig.
The company said that due to the impact of biosimilars and the prevention and control of the new crown, the group's sales in China fell by
However, there are also some multinational pharmaceutical companies who are "worried" about their performance, such as Novartis and Johnson & Johns.
Novartis' first-half 2022 performance report shows that the company's net sales revenue in the first half of the year reached US$2312 billion, basically the same as the previous year; net profit was US$916 billion, down 297% year-on-year; operating income was US$2899 billion, down 34% year-on-ye.
According to Johnson & Johnson's financial report data for the first half of 2022, the company's total global revenue was US$4446 billion, a year-on-year increase of 4%, and its net profit was US$963 billion, a year-on-year decrease of 2
It is understood that due to the continuous decline of the global market due to the impact of biosimilar drugs, many of Johnson & Johnson's sales, including Remicade (infliximab) and Imbruvica (ibrutinib), have declined, of which Remicade even fell in the first half of the ye.
2
In summary, in the first half of this year, most multinational pharmaceutical companies that maintained rapid growth in performance were driven by vaccines and products, while those whose performance declined were mostly affected by biosimila.
Performance is still declini.
It is worth waiting to see how multinational pharmaceutical companies will respond to the challenges of biosimilars and product competition in the futu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
